Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.Clinical drug investigation · 2017
   Pooled it
2. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.European journal of drug metabolism and pharmacokinetics · 2017
   Pooled it
3. Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.European journal of clinical pharmacology · 2019
   Trial
4. Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.Clinical pharmacokinetics · 2017
   Trial
5. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.Clinical drug investigation · 2016
   Trial
6. Unraveling the therapeutic landscape of approved non-peptide macrocycles.Acta pharmaceutica Sinica. B · 2025
   Review
7. Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals.npj antimicrobials and resistance · 2025
   Review
8. ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of IPharmaceuticals (Basel, Switzerland) · 2023
   Article
9. Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir.Journal of the Chinese Medical Association : JCMA · 2020
   Article
10. The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands.International journal of environmental research and public health · 2020
    Article
11. Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease.Hepatology communications · 2019
    Article
12. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.Clinical pharmacokinetics · 2018
    Article
13. Era of direct acting anti-viral agents for the treatment of hepatitis C.World journal of hepatology · 2018
    Review
14. Clinical Pharmacokinetics of Paritaprevir.Clinical pharmacokinetics · 2017
    Review
15. Clinical Pharmacokinetics of Dasabuvir.Clinical pharmacokinetics · 2017
    Review
16. Clinical Pharmacokinetics of Ombitasvir.Clinical pharmacokinetics · 2017
    Review
17. Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.Clinical drug investigation · 2017
    Article
18. Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.Clinical pharmacokinetics · 2017
    Article
19. Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Journal of clinical and translational hepatology · 2016
    Review
20. Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.